evp-4593 has been researched along with Huntington-Disease* in 2 studies
1 review(s) available for evp-4593 and Huntington-Disease
Article | Year |
---|---|
The Mystery of EVP4593: Perspectives of the Quinazoline-Derived Compound in the Treatment of Huntington's Disease and Other Human Pathologies.
Quinazoline derivatives have various pharmacological activities and are widely used in clinical practice. Here, we reviewed the proposed mechanisms of the physiological activity of the quinazoline derivative EVP4593 and perspectives for its clinical implication. We summarized the accumulated data about EVP4593 and focused on its activities in different models of Huntington's disease (HD), including patient-specific iPSCs-based neurons. To make a deeper insight into its neuroprotective role in HD treatment, we discussed the ability of EVP4593 to modulate calcium signaling and reduce the level of the huntingtin protein. Moreover, we described possible protective effects of EVP4593 in other pathologies, such as oncology, cardiovascular diseases and parasite invasion. We hope that comprehensive analyses of the molecular mechanisms of EVP4593 activity will allow for the expansion of the scope of the EVP4593 application. Topics: Humans; Huntingtin Protein; Huntington Disease; Neurons; Phenyl Ethers; Quinazolines | 2022 |
1 other study(ies) available for evp-4593 and Huntington-Disease
Article | Year |
---|---|
Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment.
Huntington's disease (HD) is a neurodegenerative disorder caused by a polyglutamine expansion within Huntingtin (Htt) protein. In the phenotypic screen we identified a class of quinazoline-derived compounds that delayed a progression of a motor phenotype in transgenic Drosophila HD flies. We found that the store-operated calcium (Ca(2+)) entry (SOC) pathway activity is enhanced in neuronal cells expressing mutant Htt and that the identified compounds inhibit SOC pathway in HD neurons. The same compounds exerted neuroprotective effects in glutamate-toxicity assays with YAC128 medium spiny neurons primary cultures. We demonstrated a key role of TRPC1 channels in supporting SOC pathway in HD neurons. We concluded that the TRPC1-mediated neuronal SOC pathway constitutes a novel target for HD treatment and that the identified compounds represent a novel class of therapeutic agents for treatment of HD and possibly other neurodegenerative disorders. Topics: Animals; Apoptosis; Calcium; Cells, Cultured; Disease Models, Animal; Drosophila; Fura-2; Glutamic Acid; Huntingtin Protein; Huntington Disease; Mice; Mice, Transgenic; Nerve Tissue Proteins; Neurons; NF-kappa B; Nuclear Proteins; Phenyl Ethers; Quinazolines; RNA Interference; RNA, Small Interfering; TRPC Cation Channels | 2011 |